Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05634174 · ClinicalTrials.gov registry record · Phase 1
ADRB3 Signaling Pathway in Human Adipose Tissue
A Phase 1 study of Obesity, Prediabetes, sponsored by University of California, San Diego.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05634174 is a Phase 1 study of Obesity, Prediabetes that is active but no longer recruiting, run by University of California, San Diego. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05634174, a Phase 1 study of Obesity, Prediabetes, is active but no longer recruiting, sponsored by University of California, San Diego.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the gene expression of the adrenergic Beta-3 receptor (ADRB3) regulation in human subcutaneous adipose tissue before and after treatment with mirabegron, an ADRB3 agonist. Gene expression will be compared across two groups, lean and obese participants. There will be a total of three study visits: Screening/Eligibility, Pre-Dose Adipose Tissue Biopsy and Post-Dose Adipose Tissue Biopsy. Participants will be given a single dose of 100mg oral mirabegron on the day of the Post-Dose Adipose Tissue Biopsy.The trial design is a single-center, phase 1, open-label, exploratory study to examine the adipocyte gene expression in adults treated with 1 dose of 100mg oral mirabegron.
Conditions Studied
Interventions
- DRUG Mirabegron
Study Locations (1)
California
- UC San Diego Altman Clinical & Translational Research Institute - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05634174
The ClinicalTrials.gov registry entry for NCT05634174 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity, Prediabetes appearing as the primary indexed condition, and to 1 intervention - of which Mirabegron is the first listed.
NCT05634174 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05634174 about?
NCT05634174 is a clinical study titled "ADRB3 Signaling Pathway in Human Adipose Tissue". This study will examine the gene expression of the adrenergic Beta-3 receptor (ADRB3) regulation in human subcutaneous adipose tissue before and after treatment with mirabegron, an ADRB3 agonist. Gene expression will be compared across two groups, lean and obese participants. There will be a total o...
What is the current status of trial NCT05634174?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-08-01. Estimated completion is 2025-12-31.
What conditions does trial NCT05634174 study?
This clinical trial studies the following conditions: Obesity, Prediabetes.
What interventions are being tested in trial NCT05634174?
The interventions under investigation include: Mirabegron (DRUG).
Who is sponsoring clinical trial NCT05634174?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05634174 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.